Avastin May Be Able to Help Patients With MDS
Introduction The authors describe the outcomes of the ARRIVE trial: A. Outcomes Relevant to MDS Outcome was significant in favor of the Avastin arm at 18 months, with an adjusted hazard ratio of 0.36 (CI=0.31–0.42). Significantly greater survival was observed in both arms, with a median survival of 17.3 months compared to 8.0 months for …